Global mRNA Vaccine Market Research Report 2023: On-going Clinical Trials, Drug Pipeline, Mergers & Acquisitions, & Product Launches – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “mRNA Vaccine Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By mRNA Type,... Read more.
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
New data from AbCellera’s T-cell engager platform demonstrates that diverse CD3-binding antibodies enable optimization of T-cell engager function beyond what is... Read more.
Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting
PASADENA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines... Read more.
New Phase 1 Dose Escalation Data Show Well-Tolerated Safety Profile and Anti-Tumor Activity for Aulos Bioscience’s AU-007 at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Preliminary evidence of anti-tumor activity observed in heavily pre-treated patients, including those whose tumors progressed through checkpoint inhibitors Further... Read more.
TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
– New data from PERIO-03 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of a TLR9 agonist... Read more.
ProfoundBio Presents Promising Data on ADC Programs, Including Early Clinical Results of Rinatabart Sesutecan in Ovarian and Endometrial Cancers, at SITC 2023
— Rina-S, a folate receptor-alpha-(FRα)-directed ADC, demonstrated encouraging anti-tumor activity in heavily pretreated patients with ovarian and endometrial... Read more.
Synthekine Presents Preclinical Data at SITC 38th Annual Meeting Demonstrating its IL-12 Partial Agonist, STK-026, Significantly Expands Therapeutic Window
MENLO PARK, Calif.–(BUSINESS WIRE)–Synthekine Inc., an engineered cytokine therapeutics company, today presented new data from preclinical studies of... Read more.
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting
– Initial Phase 2 data presented for ADCETRIS in combination with immunotherapy pembrolizumab in metastatic non-small cell lung cancer and metastatic cutaneous... Read more.
The Ultimate Off-Road Experience Awaits as EA SPORTS™ WRC Launches Worldwide Today
New Dynamic Handling Technology Enables Players to Push to Their Limit and Race for World Rally Championship Glory Watch the Launch Trailer Here REDWOOD CITY, Calif.–(BUSINESS... Read more.
EasyVista Looks to Continue Riding the Wave of a Record-Breaking Year in 2024
EasyVista’s global team gathers in Peniche, Portugal NEW YORK–(BUSINESS WIRE)–#EasyVista–EasyVista, a leader in end-to-end service management,... Read more.